Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The platelet glycoprotein Ib (GPIb) receptor is a critical component of the platelet membrane, essential for normal hemostasis and thrombosis. As part of the GPIb-IX-V complex, it mediates platelet adhesion to sites of vascular injury by binding von Willebrand factor (VWF), initiating platelet plug formation. The GPIb receptor also functions as a mechanoreceptor and regulates platelet activation through intracellular signaling pathways. Defects lead to bleeding disorders such as Bernard-Soulier syndrome, while gain-of-function mutations can cause platelet-type von Willebrand disease. GPIb is an important therapeutic target in antithrombotic drug development.
Blocks VWF and thrombin interaction with GPIbα, inhibiting platelet adhesion and activation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platelet Glycoprotein Ib Receptor (GPIb).